Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | GLA | P06280 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HBB | P68871 | 2/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | HNRNPA1 | P09651 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Camptothecin SCHEMBL6038 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL28057307 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL4304557 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL2298909 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL29351099 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL29369924 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL788063 | 1.00 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL17112859 | 0.99 | TOP1 (0.98) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL6006531 | 0.99 | TOP1 (0.98) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL3117386 | 0.99 | TOP1 (0.98) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115627629-B | Antifouling processing method for fishing net rope by utilizing hydroxyl acid ester oligomer compound antifouling agent and product thereof | 南京源健生物科技有限公司 | 2025-04-04 | — | — | CN | claimed |
| WO-2023121486-A1 | COMPOSITIONS AND COMPOUNDS FOR TREATING COVID-19 | INTERNATIONAL PATENT HOLDINGS LLC (KN) | 2023-06-29 | — | — | WO | claimed |
| EP-4689657-A1 | METHODS FOR PREDICTING AND IMPROVING THERAPEUTIC EFFICACY OF CANCER TREATMENTS AND METHODS FOR CANCER PROGNOSIS | Università Degli Studi Di Verona (IT) | 2026-02-11 | — | — | EP | disclosed |
| US-20260014160-A1 | G1T38 SUPERIOR DOSAGE REGIMES | PHARMACOSMOS HOLDING A/S (DK) | 2026-01-15 | — | — | US | disclosed |
| US-20250199015-A1 | CYCLIN-DEPENDENT KINASE 2 INHIBITORS FOR MEDICAL TREATMENT | INCYCLIX BIO, LLC (US) | 2025-06-19 | — | — | US | disclosed |
| WO-2025121445-A1 | COMBINATION THERAPY INVOLVING BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3 AND AGENTS STABILIZING OR INCREASING EXPRESSION OF CLDN18.2 | ASTELLAS PHARMA INC. (JP) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025120866-A1 | COMBINATION THERAPY INVOLVING BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3 AND AGENTS STABILIZING OR INCREASING EXPRESSION OF CLDN18.2 | ASTELLAS PHARMA INC. (JP) | 2025-06-12 | — | — | WO | disclosed |
| CN-119950749-A | Polymer-based macromolecular prodrugs | 费城儿童医院 | 2025-05-09 | — | — | CN | disclosed |
| EP-4540256-A2 | CYCLIN-DEPENDENT KINASE 2 INHIBITORS FOR MEDICAL TREATMENT | Incyclix Bio, LLC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250121083-A1 | Tumor-Associated Calcium Signal Transducer 2 (TACSTD2) Antibody-Maytansine Conjugates and Methods of Use Thereof | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2025-04-17 | — | — | US | disclosed |
| CN-115627629-B | Antifouling processing method for fishing net rope by utilizing hydroxyl acid ester oligomer compound antifouling agent and product thereof | 南京源健生物科技有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-02-16 | — | — | US | disclosed |
| CN-115177733-A | Combination therapy involving anti-claudin 18.2 antibodies for the treatment of cancer | 安斯泰来制药株式会社 | 2022-10-14 | — | — | CN | disclosed |
| CN-107873061-B | Methods and compositions for predicting treatment efficacy and prognosis of cancer treatment | 安斯泰来制药股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-07-14 | — | — | US | disclosed |
| CN-105073777-B | Combination therapy involving anti-claudin 18.2 antibodies for the treatment of cancer | 安斯泰来制药株式会社 | 2022-07-01 | — | — | CN | disclosed |
| EP-4010375-A1 | COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 AND IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF CANCER | Astellas Pharma Inc. (JP) | 2022-06-15 | — | — | EP | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014160-A1 | G1T38 SUPERIOR DOSAGE REGIMES | CDK4, CCND1, CDK8 | TOP1 217/4885ALDH1A1 4507/4885MEN1 916/4885 |
| US-20250199015-A1 | CYCLIN-DEPENDENT KINASE 2 INHIBITORS FOR MEDICAL TREATMENT | CDK2, CDK6, CDK4 | TOP1 620/4885ALDH1A1 4028/4885MEN1 978/4885 |
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | TOP1 588/4885ALDH1A1 4227/4885MEN1 2401/4885 |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | TOP1 588/4885ALDH1A1 4227/4885MEN1 2401/4885 |
| US-20250121083-A1 | Tumor-Associated Calcium Signal Transducer 2 (TACSTD2) Antibody-Maytansine Conjugates and Methods of Use Thereof | TACR3, CASR, CAMK2D | TOP1 3259/4885ALDH1A1 4213/4885MEN1 1697/4885 |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | TOP1 588/4885ALDH1A1 4227/4885MEN1 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.